Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders Clinical Trial

Official title: Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity

Status Completed

Clinical Trial Summary

1. To evaluate the safety, and efficacy of Lisdexamfetamine dimesylate in the treatment of outpatients with DSM-IV ADHD with anxiety and depressive disorder comorbidity, as well as to evaluate the effects on quality of life .

2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and depressive disorders which commonly occur with ADHD.

3. To examine the potential relationship between telomere length and Adult ADHD with comorbidity and the potential effect of treatment response.

4. To examine the potential associations with specific genes and Adult ADHD.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders
• Anxiety Disorders
• Attention Deficit Disorder with Hyperactivity
• Depression
• Depressive Disorder
• Disease

• NCT number: NCT01863459
• Study type: Interventional
• Source: Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada
• Status: Completed
• Phase: Phase 4
• Start date: April 2013
• Completion date: March 2017